It is challenging to extract LNnFP I in large quantities from natural resources. CD BioGlyco has the ability to produce LNnFP I by chemoenzymatic synthesis method or chemical synthesis method.
There are various ways to produce human milk oligosaccharides (HMOs), including extraction, chemical synthesis, chemoenzymatic synthesis, and modified microbial pathways, according to earlier research. Since there aren't enough human milk donors to meet demand, LNnFP I hard to be extracted from natural resources. To address this issue, chemical synthesis, and chemoenzymatic synthesis were created. Though they can be used for large-scale production, they still have limitations. Chemoenzymatic synthesis requires several toxic chemicals and pricey reaction substrates, which still have a lengthy reaction process. Chemical synthesis has a complex reaction procedure and poor target HMO yield.
Fig.1 The structure of LNnFP I. (CD BioGlyco)
The designed microbial pathway has received substantial study as an alternate strategy for the large-scale manufacturing and synthesis of LNnFP I because it avoids the aforementioned limitations. A variety of HMO structures can be created by using microbial fermentation and an appropriate host strain. For the modified microbial pathway, Escherichia coli, Saccharomyces cerevisiae, Bacillus subtilis, and Corynebacterium glutamicum are the primary strains that are currently used as hosts. As a result of its effective DNA molecule introduction, high level of expression, and quick growth, E. coli has been one of them that has been employed extensively in the development of HMOs.
Fig.2 Schematic representation showing the 2'-FL/3-FL production in engineered E. coli. (Lu, et al., 2021)
CD BioGlyco provides custom LNnFP I production services for clients. We have an advanced production platform, which has various programs to produce HMOs, including extraction, chemical synthesis, chemoenzymatic synthesis, and modified microbial pathways. For small-scale needs, we normally use Chemoenzymatic Synthesis and extractions; and for large-scale needs, we usually use Cell Factories (engineered microbial route) to produce LNnFP I. According to the client's needs, we provide one or multiple production methods to synthesize/produce LNnFP I-related products. In addition, we provide different scales and grades of LNnFP I production according to the client's requirements. We also provide HMO Analysis Services for helping clients' HMOs research.
CD BioGlyco offers customized LNnFP I production services for clients, based on our experienced production department we have the ability to meet serval needs of our clients. If you are interested in the production service for LNnFP I, please feel free to contact us for more detailed information. Looking forward to being your partner in the field of HMO research, and we appreciate inquiries from worldwide.
Reference:
